IXICO plc New contract worth >GBP1.0m (7896Q)
01 November 2021 - 6:00PM
UK Regulatory
TIDMIXI
RNS Number : 7896Q
IXICO plc
01 November 2021
IXICO plc
("IXICO" or the "Company")
Phase III demyelinating disorder contract award with largest
Pharma client worth >GBP1.0m
IXICO plc (AIM: IXI), the AI data analytics company delivering
insights in neuroscience, announces that it has been selected by
its largest pharma client to provide neuroimaging services for a
new Phase III clinical trial focused on a demyelinating disorder.
The study will be conducted across 100 sites in 10 countries and is
worth more than GBP1.0m over seven years .
This is the second Phase III trial in this disease area that has
been awarded to the Company in the last twelve months. This
reflects the Company's strategy to diversify into a broader range
of neurological disorders identified as having a high unmet
clinical need.
Having built an extensive portfolio of proprietary imaging data
management and analysis technologies for investigation of
neurological disorders since its inception in 2004, IXICO provides
advanced neuroimaging solutions and services across the entire drug
development lifecycle, from Phase I through to commercialisation.
The global prevalence of demyelinating diseases, conditions that
result in damage to the protective covering surrounding nerve
fibers in the brain, optic nerves and spinal cord such as multiple
sclerosis (MS), has risen across the world over the past 10 years,
increasing the need for additional drug trials and treatment
options.
Whilst this contract was already included within management's
expectations for financial performance across the year, it adds to
the Company's order book and further increases visibility of future
revenues.
Giulio Cerroni, CEO of IXICO, commented: " We are delighted to
be awarded the contract for this demyelinating study. Our success
in being awarded two such studies during 2021 supports our decision
to invest in developing new analytics solutions to a broad range of
neurological disorders, including demyelinating diseases which
represent an important area of research within CNS. Our mission is
to support our clients in their tireless efforts to bring potential
treatments to patients suffering from neurological disorders, and
this new contract reflects the confidence that clients place in
IXICO as their trusted neuroimaging partner for their pivotal CNS
studies."
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales
Walbrook PR Ltd IXICO@walbrookpr.com
Paul McManus / Lianne Applegarth +44 (0)20 7933 8780
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTFLFVEISLAFIL
(END) Dow Jones Newswires
November 01, 2021 03:00 ET (07:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024